Division of Endocrinology and Diabetes Clinical Studies

1 - 7 of 7

Medtronic 780G System

This study will evaluate the safety and effectiveness of the MiniMed 780G insulin pump system used in combination with the DS5 CGM in type 1 diabetic pediatric participants in a home setting. 

PETITE-T1D

The purpose of this study is to evaluate the safety and pharmacokinetics (drug levels in the blood) of teplizumab in children less than 8 years old. The study will also assess if your child stays in Stage 2 T1D or progresses to Stage 3 T1D. Your child may join the study only if they are in Stage 2 T1D.

Previous studies in adults and children older than 8 years of age suggest that taking teplizumab, a drug that affects your child’s immune system, may stop, delay, or decrease the attack on the cells that make insulin. This slowing or blocking of the immune attack may reduce the risk of short-term and long-term consequences of T1D.

To join this study, your child must have been diagnosed with Stage 2 T1D based on two positive T1D-related antibodies and confirmed dysglycemia (abnormal blood sugar levels) based on an oral glucose tolerance test, fasting plasma glucose test, or an increase in a blood test called the hemoglobin A1c. 

The study is “open-label.” That means that if your child qualifies for the study, your child will receive teplizumab. There is no placebo in this study.

RM-493-035: Setmelanotide in Patients with Gene Defects in the MC4R Pathway

The purpose of this study is to find out if an investigational drug called setmelanotide (RM-493) can help control body weight in people with certain genetic modifications in their genes that play a key role in the regulation of body weight. Males and females, age 6 to 65, with obesity and certain genetic variants (MC4R pathway) may be eligible to participate. If you are confirmed eligible for the study, then participation will last up to 64 Weeks. Participants will complete Screening (Up to 8 Weeks), Double-Blind Treatment (Up to 52 Weeks), and Follow-Up Period (4 Weeks). Participants will complete research procedures including physical exams, blood draws, ECGs, and questionnaires. Participant will also need to self-inject the study drug once daily for the duration of their participation.

Designate - Siplizumab in T1DM

The goal of this study is to identify a safe dosing regimen for siplizumab in participants with type 1 diabetes. Siplizumab is a drug used to help treat recent onset type 1 diabetes mellitus (T1DM). This study is interested in participants aged 18-45 years with T1DM, who are within 18 months of receiving their diagnosis. Participants will be randomized (selected at random by the study team) to one of four possible treatment groups. All groups will receive weekly siplizumab doses administered subcutaneously (injected into the body through the skin) for a total of 12 weeks.

MRI Assessment of NAD+

NAD+ (nicotinamide adenine dinucleotide) is an important substance found in the body that plays a role in energy metabolism and overall health. The purpose of this research study is to test the performance of a new magnetic resonance imaging (MRI) technique (spectroscopy) to measure NAD+ metabolism in brain and skeletal muscle. MRI provides pictures of the inside of the body and information about chemicals the body makes.
We are seeking to enroll males and females with Friedrich’s Ataxia (FA) as well as healthy matched volunteers, 18 years of age and above. Pregnant females excluded for safety purposes.

Canagliflozin in Children with Type 2 Diabetes

The goal of this study is to investigate the efficacy and safety of Canagliflozin (which is experimental) in children and adolescents ages 10 to 18 years old with Type 2 diabetes and poor control (i.e., an HbA1c of 6.5% to 10.5%). Study drug or placebo would be taken alone or with metformin or insulin as needed. Monitoring tests include blood, urine, physical exams, vital signs, blood sugar and ketone monitoring, diabetes management counseling.

NCGD

The purpose of this research study is to learn more about Graves’ disease and PTC/Hypothyroidism, How it effects brain function and brain function changes after starting medical treatment.